Literature DB >> 24129834

Dermal exposure to a compounded pain cream resulting in severely elevated clonidine concentration.

Adam C Pomerleau1, Casey E Gooden, Corinne R Fantz, Brent W Morgan.   

Abstract

INTRODUCTION: Clonidine is an imidazoline derivative antihypertensive medication that is also used as adjunctive therapy for neuropathic pain disorders via topical administration. Clonidine overdose can manifest both central and peripheral alpha-adrenergic agonist effects. CASE REPORT: A 23-year-old man presented to an emergency department with altered mental status, bradycardia, and hypertension after suspected overdose. He had rubbed a specially compounded medicinal cream over his entire body containing clonidine 0.2 % (w/w), gabapentin 6 %, imipramine 3 %, ketamine 10 %, lidocaine 2 %, and mefenamic acid 1 %. The patient presented with severe hypertension, bradycardia, and altered mental status. He was found to have a subarachnoid hemorrhage and was treated for hypertensive emergency. Toxicological analysis of initial blood samples revealed a serum clonidine concentration of 5,200 ng/ml. At 6-month follow-up, the patient had made a full recovery. DISCUSSION: There are limited reports of topical clonidine toxicity, and to our knowledge, this case involves the highest concentration yet reported following clonidine overdose by any route of exposure. The severely elevated serum clonidine concentration found in our patient demonstrates the possibility of toxicity resulting from inappropriate use of such a product. At high serum concentrations, the pharmacodynamic effects of clonidine appear to cause significant peripheral alpha-1 adrenergic stimulation. Toxicologists should be aware of the increasing use of topical clonidine preparations for the treatment of neuropathic pain and the potential for toxicity.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24129834      PMCID: PMC3951633          DOI: 10.1007/s13181-013-0331-x

Source DB:  PubMed          Journal:  J Med Toxicol        ISSN: 1556-9039


  12 in total

1.  An evaluation of the quality of pharmaceutical care: a study of the pharmacist's compounding behavior.

Authors:  T R Temple; A A Nelson
Journal:  Drug Intell Clin Pharm       Date:  1975-11

2.  Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy.

Authors:  Claudia M Campbell; Mark S Kipnes; Bruce C Stouch; Kerrie L Brady; Margaret Kelly; William K Schmidt; Karin L Petersen; Michael C Rowbotham; James N Campbell
Journal:  Pain       Date:  2012-06-08       Impact factor: 6.961

Review 3.  Central alpha-adrenergic systems as targets for hypotensive drugs.

Authors: 
Journal:  Rev Physiol Biochem Pharmacol       Date:  1978       Impact factor: 5.545

4.  Clonidine patch toxicity.

Authors:  J M Harris
Journal:  DICP       Date:  1990-12

5.  Hypertensive crisis and myocardial infarction following massive clonidine overdose.

Authors:  C B Frye; M A Vance
Journal:  Ann Pharmacother       Date:  2000-05       Impact factor: 3.154

6.  Pharmacokinetics of transdermally delivered clonidine.

Authors:  T R MacGregor; K M Matzek; J J Keirns; R G van Wayjen; A van den Ende; R G van Tol
Journal:  Clin Pharmacol Ther       Date:  1985-09       Impact factor: 6.875

7.  "Cloniderm" toxicity: another manifestation of clonidine overdose.

Authors:  C A Killian; R J Roberge; E P Krenzelok; C L Stonage
Journal:  Pediatr Emerg Care       Date:  1997-10       Impact factor: 1.454

8.  A 1000-fold overdose of clonidine caused by a compounding error in a 5-year-old child with attention-deficit/hyperactivity disorder.

Authors:  M J Romano; A Dinh
Journal:  Pediatrics       Date:  2001-08       Impact factor: 7.124

9.  Clonidine patch ingestion in an adult.

Authors:  J H Raber; C Shinar; S Finkelstein
Journal:  Ann Pharmacother       Date:  1993-06       Impact factor: 3.154

10.  Toxicity from a clonidine suspension.

Authors:  Mariya Farooqi; Steven Seifert; Susan Kunkel; Mary Johnson; Blaine Benson
Journal:  J Med Toxicol       Date:  2009-09
View more
  2 in total

1.  A polyspecific drug/proton antiporter mediates diphenhydramine and clonidine transport at the mouse blood-retinal barrier.

Authors:  Hélène Chapy; Pascal André; Xavier Declèves; Jean-Michel Scherrmann; Salvatore Cisternino
Journal:  Br J Pharmacol       Date:  2015-08-10       Impact factor: 8.739

2.  Systemic Adverse Events Associated with Compounded Topical Pain Products.

Authors:  Jenny Kim; Karen Konkel; S Christopher Jones; Lynda McCulley
Journal:  Drug Saf       Date:  2020-05       Impact factor: 5.606

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.